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Fluorescence studies of the binding of amphiphilic 
amines with phospholipids 
Jane Y. C. Ma,’ Joseph K. H. Ma,** and Kenneth C. Weber’” 
NIOSH* and the School of Pharmacy, West Virginia University, * *  Morgantown, West Virginia 26505 
Abstract The binding characteristics of several amine drugs 
with dispersed phospholipids (phosphatidylcholine, phosphati- 
dylserine, and phosphatidylglycerol) have been studied using the 
fluorometric method and l-anilino-8-naphthalene sulfonate and 
1,6 diphenyl-1,3,5-hexatriene as fluorescence probes. The results 
show that amphiphilic amines, such as chlorphentermine, inter- 
act with phospholipids via both ionic and hydrophobic forces. 
The ionic interaction, which occurs between the protonated 
amine group of the drug and the phosphate oxygen of the lipid, 
changes the amphiphilic characteristics of the lipid by reducing 
the number of negative charges on the lipid vesicles, and inhibits 
the Caw-dependent lipid hydrolysis by blocking the Car bind- 
ing sites on the lipid vesicles. The hydrophobic interaction, 
which involves the nonpolar moieties of the drug and the lipid, 
is of primary importance to the overall drug-lipid binding stabil- 
ity. Drugs without a strong hydrophobic moiety, such as 
dopamine, do not interact with phospholipids. - Ma, J. Y. C., 
J. K. H. Ma, and K. C. Weber. Fluorescence studies of the 
binding of amphiphilic amines with phospholipids. J Lipid h. 
1985. 26: 735-744. 
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Cationic amphiphilic drugs such as chlorphentermine 
and imipramin have been shown to cause phospholipid 
storage disorders in rat lungs characterized by the 
accumulation of large, phospholipid-laden alveolar mac- 
rophages (1-4). In a study of the pharmacokinetics of 
phentermine and chlorphentermine in rats, Liillmann, 
Rossen, and Seiler (5) demonstrated that the drug- 
induced lipidosis may be directly related to the tissue con- 
centration of the drug. Their results show that phenter- 
mine, which does not induce lipidosis, is more readily 
eliminated from tissues than is chlorphentermine in rats 
treated with a single dose. The results also show that in 
chronically treated rats there is a steady increase in tissue 
accumulation of chlorphentermine but not phentermine, 
suggesting that the binding of the amphiphilic drug to the 
tissue components, or perhaps to phospholipids, may be 
required in order to produce lipidosis. 
In the attempt to further elucidate the mechanism of 
the drug-induced lipidosis, several studies dealing with 
drug-lipid interactions have been reported. Liillmann, 
Liillmann-Rauch, and Wassermann (6, 7) proposed that 
the cationic amphiphilic amines interact with phospho- 
lipids via both electrostatic and hydrophobic forces, and 
that such binding may lead to impaired lipid metabolism 
by changing the physicochemical properties of the lipids 
such that they become less readily attacked by phospho- 
lipases. Indeed, a study by Grabner (8) has shown that 
chlorphentermine inhibits the hydrolysis of phosphatidyl- 
choline by bee venom phospholipase A*. The importance 
of the hydrophobic interaction between the drug and 
lipids has been demonstrated by Seydel and Wassermann 
(9, 10). They found that several amphiphilic drugs 
including chlorphentermine, but not phentermine, are 
capable of binding with phosphatidylcholine and phos- 
phatidylethanolamine via hydrophobic interaction be- 
tween the nonpolar moieties of the drugs and the lipids. 
They further showed that drugs such as chlorphentermine 
do not bind appreciably with pancreatic phospholipase 
A*, suggesting that the drug-lipid interaction may be 
directly responsible for the inhibition of phospholipid 
catabolism. 
To provide more insight as to the nature of the drug- 
lipid interactions and the mechanism of drug inhibition of 
phospholipid catabolism, we have carried out binding 
studies of phospholipids with several amine drugs of 
varying amphiphilic characteristics by using a fluoro- 
metric technique with l-anilino-8-naphthalenesulfonate 
(ANS) and 1,6-diphenyl-1,3-5-hexatriene (DPH) as flu- 
orescence probes. Phospholipids are amphiphilic mole- 
cules that consist of a hydrophilic phosphate head group 
and long aliphatic chains that are hydrophobic in nature. 
The phosphate moiety exhibits a negatively charged 
- 
Abbreviations: ANS, 1-anilino-8-naphthaleneaulfonate; DPH, 1,6- 
diphcnyl-1,3,5-huratriene; DPPC, dipalmitoylphasphatidylcholine (1,2- 
dipalmitoyl-m-glycero-3-phoaphocholine); LPC, lyaophosphatidylcho- 
line (l-palmitoyl-m-glycero-3-phosphocholine); PS, phoaphatidylserine; 
DPPG, 1,2-dipalmitoyl-m-glycero-3-phmphogl~erol. 
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oxygen group which is capable of interacting with cationic 
species. Thus, it is not surprising that phospholipids 
exhibit strong affinity for the highly cationic amphiphilic 
amines. ANS is an anionic fluorescent agent which has 
been shown to be a valuable probe for the study of lipid 
interactions involving the hydrophilic phosphate moiety 
(11, 12). DPH, which has been shown to bind to the 
interior of the lipid vesicles (13-15), is used as a probe to 
characterize the hydrophobic interaction between the 
cationic amphiphilic amines and phospholipids. 
EXPERIMENTAL 
Materials 
The fluorescence probes, 1-anilino-8-naphthalene sul- 
fonate (ammonium salt; ANS) and 1,6-diphenyl-1,3,5- 
hexatriene (DPH), were obtained from Aldrich Chemical 
Co. (Milwaukee, WI) and from Molecular Probes, Inc. 
(Junction City, OR), respectively. Dopamine hydrochlo- 
ride, ephedrine hydrochloride, and phenylpropanolamine 
hydrochloride were purchased from Sigma Chemical Co. 
(St. Louis, MO), and the hydrochloride salts of chlor- 
phentermine and phentermine were kindly supplied by 
Dr. M. Reasor of the Department of Pharmacology, West 
Virginia University School of Medicine. Phospholipase 
A2 from bee venom was obtained from Sigma Chemical 
Company. The chloride salts of Ca2*, Ba2+, and Mg" 
were obtained from Fisher Scientific Company. 
The synthetic 1,2-dipalmitoyl-sn-glycero-3-phosphocho- 
line (DPPC) and 1-palmitoyl-sn-glycero-3-phosphocholine 
(LPC) were obtained from Calbiochem-Behring Corp. 
The synthetic 1,2-dipalmitoyl-sn-glycero-3-phosphoglyc- 
erol (DPPG) and phosphatidylserine (PS) from bovine 
brain were obtained from Avanti Polarlipids, Inc. The 
phospholipid vesicles dispersed in (0.01 M) Tris buffer 
(pH 7.0) were prepared by sonication of lipid solutions 
under nitrogen using a heat system W375 sonifier. Sam- 
ples of DPPC and DPPG were sonicated for 30 min at 
5OoC, whereas samples of PS were sonicated for 10 min 
at 4OC. Small vesicles of these solutions were fractionated 
from the larger liposomes by centrifugation at 105,000 g 
for 60 min. The concentration of phospholipids was 
determined by measuring the inorganic phosphorus using 
the method of Bartlett (16). 
Instruments 
The fluorescence measurements were carried out using 
an Aminco-Bowman spectrophotofluorometer (American 
Instrument Co., Silver Spring, MD) equipped with a 150 
W Xenon lamp, a 1P21 photomultiplier tube, and an X-Y 
spectral recorder. Standardization of the fluorescence 
intensity of the instrument was routinely carried out 
using a solid sample of tetraphenylbutadiene (excitation, 
348 nm; emission 422 nm) obtained from Atarna Sci- 
entific, Ltd., Swarthmore, PA. Unless otherwise men- 
tioned, the temperature of the fluorometer cell compart- 
ment was controlled for all experiments at 25 f 0.1OC 
using a circulatory water bath from Forma Scientific, Inc., 
Marietta, OH. 
Fluorometric binding studies 
Binding studies of the amphiphilic amines with phos- 
pholipids were carried out in 0.01 M Tris buffer (pH 7.0) 
using a fluorescence probe technique. To characterize the 
hydrophobic interaction between the amines and phos- 
pholipids, DPH was used as a fluorescence probe. The 
lipid-bound DPH shows intense fluorescence at 440 nm 
(excitation, 368 nm), while the non-bound DPH does not 
exhibit fluorescence in aqueous solution. Studies of the 
drug-lipid interaction using DPH as a probe were based 
on a competitive binding mechanism in which the 
quenching of DPH fluorescence by the addition of drug 
was assumed to be due to the binding of the drug at or 
near the DPH binding sites on the lipid. For the study of 
the ionic interaction between the drugs and phospho- 
lipids, ANS was used as the fluorescence probe. The 
relative binding strength of the drugs was evaluated based 
on the effect of the drugs on the binding of ANS to the 
lipids. 
Stock solutions of 
DPH in tetrahydrofuran M) were freshly prepared 
and protected from light exposure. To determine the bind- 
ing of DPH to DPPC, samples containing a constant 
concentration of DPPC and various concentrations of 
DPH in the range of 5 x 10-8-5 x IOw6 M were incubated 
at 5OoC for 60 min. After the samples were allowed to cool 
to room temperature, 2 ml was used for measurement of 
fluorescence intensity. The fluorescence was then plotted 
as a function of DPH concentration. This experiment was 
repeated using different lipid concentrations. When the 
DPPC concentration was M or above, the fluores- 
cence was found to be linear with DPH concentration, 
suggesting that all DPH molecules in the solution are in 
the bound form. These data were used to calculate the 
bound and free concentrations of DPH in a solution of 
lower DPPC concentration ( - M); i.e., the fraction of 
bound-DPH in the solution of lower DPPC concentration 
was taken to be the ratio of its fluorescence with that of 
the solution containing loe3 M DPPC at the same total 
concentration of DPH. 
The binding constant and the binding capacity be- 
tween DPH (probe) and DPPC vesicles were determined 
using equation 1, assuming equal binding strength for all 
binding sites (Scatchard equation): 
- = n K - v K  
Binding studies using DPH a.s a probe. 
Eq. 1 )  
V 
[PI 
where v is the number of moles of bound probe per mole 
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of lipid; [PI is the free concentration of the probe, DPH; 
n is the maximum value of v which indicates the binding 
capacity of the lipid for DPH; and K is the binding 
constant. For the competitive binding studies, fluoro- 
metric titrations of solutions containing 5 x lO-5 M DPPC 
and a constant concentration of DPH with  stock solutions 
of the amine drugs were performed, and the quenching of 
the fluorescence was recorded as a function of drug con- 
centration. The fluorescence data were  used to calculate 
the free and bound concentrations of DPH in the pres- 
ence of the drug. Among the drugs used  in this study,  only 
chlorphentermine exhibited a significant effect on the 
fluorescence of lipid-bound DPH at room temperature. 
The binding of chlorphentermine to DPPC was deter- 
mined using equation 2. This equation was derived  from 
the competitive binding mechanism assuming that the 
drug competes  for nl of the n probe binding sites  with an 
intrinsic binding strength of K1: 
(n - vl)vl = nlKl - vlKl . Eq. 2) 
(n - v* - vi) [Dl 
In this equation, v* is the ratio of bound-probe per total 
lipid concentration in the presence of drug; v1 is the ratio 
of bound-drug per total lipid concentration; nl is the 
maximum value of v1 which indicates the probe binding 
sites  which  may  be  replaced by drug binding; [Dl is the 
free drug concentration; and K1 is the binding constant 
for the drug-lipid interaction. The term n has  been pre- 
viously defined. For the calculation of nl and K1 using 
equation 2, v8 was determined from the fluorescence 
data, whereas v1 was calculated from equation 3, after n 
and K had been determined using equation 1: 
V* v l = n - v * - -  Eq. 3) 
[P]*K . 
The term [PI* represents the free concentration of the 
probe. in the presence of drug. After v1 was determined, 
[Dl was taken to be the difference  between the total drug 
concentration and the product of v i  and total lipid 
concentration. 
Binding studies using ANS as a pmbe. ANS  exhibits weak 
fluorescence at 510 nm (excited at 380 nm) in aqueous 
solution alone, but shows enhanced fluorescence intensity 
at 480 n m  (excited at 380 nm) when bound to DPPC. The 
fluorescence of the lipid-bound ANS was further in- 
creased by the addition of amphiphilic drugs, suggesting 
the formation of a drug-lipid-ANS  complex in the 
ternary system. To evaluate the binding phenomena, the 
emission  coefficient (A) of the different  species of  ANS, at 
480 nm delined as the fluorescence intensityhpecies con- 
centration ratio, was determined. 
For the binary ANS-lipid system, fluorometric titra- 
tions of solutions containing a constant concentration of 
phospholipid  with a stock solution of ANS were carried 
M4 
out at several lipid concentrations. At relatively high 
concentrations of lipid (1 x lo-’ M) and low concentra- 
tion of ANS (in the order of 10-7-10-6 M), the titration 
showed a linear relationship between  fluorescence inten- 
sity and ANS concentration. The slope of the linear plot 
was taken to be the emission  coefficient of the binary ANS 
complex (Ab). The binding of ANS to phospholipid was 
determined using solutions containing 2 x lO-5 M lipid 
and varying concentrations of  ANS. The fraction of 
bound ANS, x,, in these solutions was calculated ac- 
cording to the following equation: 
xb = (Fb - Fo)/(Ab - Ao) Eq, 4 )  
where Fb and Fo are the fluorescence  intensities  for soh- 
tions with and without lipid, while & and & are the 
emission coefficients for the lipid-bound and free ANS, 
respectively. The values of A, and Ab for DPPC at 480 
nm were determined to be 0.5 x lo6 and 68 x lo6, 
respectively.  From the value of x,, the concentrations of 
free and bound ANS were calculated for each solution 
and the data were treated using equation 1. 
In the ternary system, fluorometric titrations of solu- 
tions containing 1O-2 M drug and constant concentration 
of phospholipid  with a stock  solution of ANS were carried 
out  at several lipid concentrations. The  drug concentra- 
tion of 1O-2 M was found to be sufficient to saturate the 
lipid’s drug-binding sites. At the relatively high concen- 
tration of lipid (1 x lo-’ M) and low concentrations of the 
probe, the plot of fluorescence intensity versus  ANS  con- 
centration was linear, and the slope  of the linear plot was 
then taken to be the emission coefficient of the ternary 
ANS  complex (At). For the quantitative determination of 
the binding of ANS to lipid saturated with drug binding, 
a solution containing 2 x lO-5 M lipid and U T 2  M drug 
was titrated with a stock solution of ANS and the fluores- 
cence of each titration increment was measured. The free 
and bound concentrations of ANS corresponding to each 
total ANS concentration along the titration curve were 
calculated using A, in the same manner as  described for 
the binary system. The binding parameters were then 
determined using equation 1. In this system, since the 
fluorescence change is due to the formation of the drug- 
lipid-ANS ternary complex, the value of n should also 
indicate the binding capacity of the lipid for the amphi- 
philic drug. 
RESULTS AND DISCUSSION 
The  binding  nature of amphiphilic  amines 
with phospholipids 
ANS, a relatively  nonfluorescent  molecule, shows 
intense fluorescence with a blue  shift of its emission 
maximum when bound to macromolecules capable of 
providing a hydrophobic environment (17). Studies have 
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shown that ANS binds to phospholipids in such a way that 
the anionic sulfonate group is oriented toward the hydro- 
philic head group of the lipid (11, 12, 18). Due to ionic 
interaction leading to charge neutralization, such binding 
and the fluorescence enhancement are obviously stronger 
for lipids possessing a non-hindered positive nitrogen 
such as DPPC. Phospholipids contain a negative phos- 
phate oxygen group at physiological pH. Thus, further 
enhancement of the fluorescence of lipid-bound ANS may 
be brought about by the addition of cationic species 
capable of binding to the negative oxygen group. The 
effects of two cationic species, Ca2+ and chlorphenter- 
mine, on the fluorescence of DPPC-bound ANS are 
shown in Fig. 1. Both Caz+ and chlorphentermine in- 
crease the fluorescence of DPPC-bound ANS, suggesting 
that these ions interact with the negative phosphate 
oxygen group and provide a more hydrophobic environ- 
ment in the vicinity of the ANS molecule. The results also 
show a greater fluorescence enhancement for the mono- 
valent chlorphentermine ion than that for the divalent 
Ca2+. The negative phosphate oxygen group of the lipid 
as a binding site for Ca2+ has been well established in 
several studies (11, 12). 
The effects of chlorphentermine on the fluorescence of 


















Fig. 1. Fluorescence spectra of solutions containing 5 x lO-5 M ANS 
(A) and in the presence of B) 9.36 x 1O-6 M DPPC, C) 9.36 x 1O-6 M 
DPPC, and lo-' M Ca", and D) 9.36 x lo-6 M DPPC and lo-' M chlor- 
phentermine in pH 7.0, 0.01 M Tris buffer. The spectra were obtained 
with an excitation at 380 nm. In the absence of DPPC, CaZ+ or chlor- 
phentermine did not show significant effects on the ANS spectrum. 
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Fig. 2. Plots of fluorescence intensity, F-Fo, as a function of lipid con- 
centration for solutions containing 5 x lO-5 M ANS and varying con- 
centrations of lipids (circles, DPPC; triangles, PS; squares, DPPG) in 
the absence (open symbols) and presence (fdled symbols) of lo-' M 
chlorphentermine. F-Fo is the difference in fluorescence between the 
above solutions and the solution of 5 x 10'' M ANS. The drug and ANS 
concentrations used are sufficiently high to saturate the lipid binding 
sites, so that the value, F-Fo, is proportional to the concentration of lipid- 
bound ANS. The fluorescence intensity was measured at 480 nm with 
excitation at 380 nm. 
The binding of ANS with DPPG and PS did not result in 
a significant increase of ANS fluorescence probably due 
to the lack of a non-hindered positive nitrogen group in 
these lipids. However, strong fluorescence enhancement 
was observed when the system contained chlorphenter- 
mine. The results further suggest that chlorphentermine 
interacts with the negative oxygen group of the lipid's 
phosphate moiety. 
The ionic interaction of phospholipids is of significant 
consequence to the lipid's solubility and surface activity. 
At high concentrations of lipid and ANS, addition of 
chlorphentermine results in a precipitation of the lipid 
due to charge neutralization and the subsequent loss of its 
amphiphilic characteristics. 
DPH is a nonfluorescent molecule in aqueous solution, 
but is known to bind to the interior of lipid vesicles and 
gives intense fluorescence at 440 nm (13-15). The effect of 
chlorphentermine on the binding of DPH to DPPC 
vesicles at room temperature and at 45OC is shown in 
Fig. 3. The addition of chlorphentermine quenches the 
fluorescence of the lipid-DPH solution, probably indi- 
cating a binding displacement of DPH by chlorphenter- 
mine which binds in close proximity to the DPH binding 
sites. This quenching effect is much greater at a tempera- 
ture above the transition temperature of the lipid (45OC) 
than at lower temperature (25OC), suggesting that the 
amphiphilic drug exhibits only a limited penetration of 
the interior of the lipid vesicles, i.e., the binding of chlor- 
phentermine affects only those DPH binding sites near 
the vesicel surface. Nevertheless, these results show a 
second binding mode for the drug-lipid interaction which 
involves the hydrophobic interaction between the non- 
polar moieties of the two species. 
Hydrophobic interactions are important to the overall 
binding of drugs to phospholipids. Table 1 shows the 
effect of several amine drugs of varying amphiphilic 
properties (as indicated by their structures) on the fluores- 
cence of DPPC-bound ANS. The value At/Ab represents 
the fluorescence enhancement of the ternary complex over 
the binary complex. It can be seen that dopamine, which 
is not amphiphilic in nature due to the presence of the 
catechol group in their hydrophobic moiety, shows little or 
no interaction with DPPC. On the other hand, relatively 
strong amphiphiles, such as phentermine and chlorphen- 
termine, exhibit relatively strong interactions with phos- 
pholipid. 
The above results show a binding nature between the 
drug and lipid that is consistent with the amphiphilic 
characteristics of both species, i.e., the binding involves 
both hydrophobic and ionic interactions. The results indi- 
cate that, while the ionic interaction is most likely a cause 
for drug effect on surface activity of phospholipids, the 
hydrophobic interaction may serve as a stabilizing force 
for the binding of drug to lipid vesicles. One may consider 
that the hydrophobic interaction provides an orientation 
of the two species such that the ionic interaction is possible. 
Quantitative aspects of the drug-lipid interaction 
A Scatchard plot (equation I) for the binding of DPH 
to DPPC at 25OC is shown in Fig. 4. From the straight 
line plot, the values of n and K were calculated to be 
0.0167 and 2.85 x IO6 W, respectively. These results 
suggest a strong hydrophobic binding between DPH and 
DPPC with a binding ratio of 1 DPH molecule per 60 
lipid molecules. Since the number of lipid molecules per 
vesicle in unknown, the number of binding sites per lipid 
vesicle was not calculated. A plot that illustrates the 
competitive binding between chlorphentermine and DPH 
to DPPC (equation 2) is shown in Fig. 5. The plot shows 
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Fig. 3. EBect of chlorphentermine on the binding of DPH to DPPC at 25OC (circles) and at 45OC (stars) as indi- 
cated by fluomcnce quenching. All solutions contain 5 x lom5 M DPPC, a constant concentration of DPH, and 
varying concentrations of chlorphentermine (A: 5 x lo-’ M; B: 8 x lo-’ M; C: 5 x lo-’ M; D 1.0 x 1O-6 M). Flu- 
orescence measurements were made at 440 nm with excitation at 368 nm. 
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TABLE 1. Chemical structure of selected amines and their effect on the fluorescence of DPPC-bound ANS 
P a *@ CH- C - NH 
3 2  
Ring P a Amino AJA; 
Dopamine 3-OH,4-OH H H,H H 1 .o 
Phenylpropanolamine O H  H,CHs H 1.50 
Ephedrine O H  H,CHJ CHI 1.45 
Phentermine H CHs,CHs H 3.70 
Chlorphentermine 4-C1 H CHs,CH, H 7.09 
*At and Ab are the emission coefficients of ANS in the ternary (drug-lipid-ANS) and in the binary (lipid-ANS) 
complexes, respectively. 
a straight line from data obtained in three separate 
experiments, and gives a value of 0.004 for nl and 8.04 
x lo3 M-’ for K1. These results suggest that about one- 
fourth of the bound DPH may be replaced by the binding 
of chlorphentermine. The relatively weak hydrophobic 
binding strength as indicated by K1 suggests that these 
binding sites are near the surface of the lipid vesicles. 
Other amine drugs used in this study, which are less 
amphiphilic than chlorphentermine, did not quench the 
fluorescence of lipid-bound DPH. 
The Scatchard plot for the binding of ANS to DPPC is 
shown in Fig. 6. From the slope and the intercept of the 
plot, the values of n and K were calculated to be 0.034 and 
1.4 x lo5 M-’, respectively. These results indicate a strong 
binding between the probe and the lipid with a molar 
binding ratio of about 1:30 (ANS:DPPC). The binding of 
the anionic probe to either PS or DPPG was not indicated 
by the fluorometric method, probably because these lipids 
exhibit an overall negative charge on the phosphate 
moiety at neutral pH. In the ternary systems, however, 
the anionic probe was found to interact with all three 
phospholipids. The results are shown in Fig. 7, where the 
binding data for solutions containing lo-* M chlorophen- 
termine, 2 x lO-5 M lipid, and varying concentrations of 
ANS are treated with equation 1. The data for the ANS- 
Fig. 4. Scatchard plot (equation I) for the binding of DPH to DPPC 
at 25OC measured at two lipid concentrations (0 5 x lo-’ M; 0 
2 x 10-5 MI. 
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Fig. 5. Binding of chlorphentermine to DPPC measured by using 
DPH as a probe (equation 2). Data were obtained from solutions con- 
taining 2 x io-’ M DPPC, varying concentrations of chlorphentermine 
and 0) 5 x lo-’ M DPH; *) 8 x lo-’ M DPH; and 0) 2 x 1O-6 M 
DPH. 
DPPC binding (curve A) shows a biphasic linear plot, 
indicating that in the presence of chlorphentermine the 
lipid has two classes of binding sites for the probe. At 
relatively low ANS concentrations, the plot is linear and 
gives a binding constant of 1.4 x lo5 M-'. This value is 
the same as that calculated for the binary ANS-DPPC 
binding, suggesting that the binding of the amphiphilic 
drug does not affect the primary binding of ANS to the 
lipid. However, the drug-lipid binding induces a secon- 
dary binding between the probe and the lipid as indicated 
by the linear plot in the region of high ANS concentra- 
tions. In the cases of PS and DPPG, the linear plots 
(curves B and C, respectively) show a single class of bind- 
ing sites. Since the fluorometric method does not measure 
the primary binding of the probe to PS and DPPG, these 
data probably represent the drug-induced binding be- 
tween the probe and the lipids. The overall binding 
capacity, n, calculated from Fig. 7 for all lipids is 0.067, 
which is twice the value calculated for the ANS-DPPC 
binary system. The chlorphentermine effect may be 
attributed to the ability of the cationic drug to neutralize 
the negative charges of the lipid and thus create a condi- 
tion more conducive for the probe binding. The addi- 
tional binding capacity for the probe also reflects the 
binding capacity of the lipid for the amphiphilic drug. 
DPPC are shown in Fig. 8. For comparison, the solid line 
Fig. 6. Scatchard plot for the binding of ANS to DPPC for solutions The effects Of Other amines On the binding Of ANS to 
containing 2 x lO-5 M DPPC and varying concentrations of ANS. 
Fig. 7. Effect of chlorphentermine on the binding of ANS to A) DPPC, B) PS, and C) DPPG. Data were obtained 
from solutions containing 2 x lO-5 M lipid, IO-* M chlorphentermine, and varying concentrations of ANS and 
treated using equation 1. 
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Fig. 8. Effect of dopamine (a), phenylpropanolamine (O), ephedrine (*), and phentermine (A)  on the binding 
of ANS to DPPC. Data were obtained from solutions containing 2 x lO-5 M DPPC, lo-' M drug, and varying con- 
centrations of ANS and treated using equation 1. 
represents the binding plot for the ANS-DPPC binary 
system. As can be seen, dopamine has no effect on the 
ANS binding, suggesting that it does not interact with the 
lipid. However, the binding of phenylpropanolamine, 
ephedrine, and phentermine to DPPC is clearly indicated 
by their ability to induce a secondary binding for ANS, 
which occurs at relatively high ANS concentrations. 
Based on their relative effects on the ANS-DPPC binding 
shown in Figs. 7 and 8, it may be concluded that 
these drugs interact with the lipid in the following 
decreasing order of affinity: chlorphentermine > phenter- 
mine > ephedrine > phenylpropanolamine > dopamine. 
Thus, although ANS is used to indicate the ionic 
interaction of the amines with phospholipid, it shows that 
the binding affinity of the amines to the lipid is closely 
related to the hydrophobicity of the drug's nonpolar 
moiety. The results on phentermine and chlorphenter- 
mine are consistent with those reported in the literature 
(9, 10, 19). 
Drug inhibition of DPPC hydrolysis by 
phospholipase A2 
Phospholipase A2 activity has been monitored using 
ANS as a fluorescence probe. Fig. 9A shows the change 
of ANS fluorescence as a function of time after the addi- 
tion of 0.25 gg/ml of phospholipase A2 to a solution con- 
taining 1 x lo-5 M DPPC, 5 x lO-5 M ANS, and 6 x lO-3 
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M Ca2+. In the absence of the metal ion, the fluorescence 
did not change as a function of time upon addition of the 
enzyme. The enzymatic hydrolysis of DPPC into LPC is 
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Fig. 9. Fluorescence change (AF) as a function of time upon addition 
of 0.25 pglml phospholipase A, to solutions containing 1 x lO-5 M 
DPPC, 5 x lO-5 M ANS, 6 x lo-' M Ca", and in the absence (A) and 
presence of 6 x lo-' M chlorphentermine (B). Drug inhibition of 
enzyme activities is indicated by the reduction of fluorescence en- 
hancement. 
from the transformation of the Ca*+-DPPC-ANS com- 
plex into the Ca2'-LPC-ANS complex. The data shown 
in Fig. 9 are consistent with literature results (20, 21). It 
is also interesting to point out that the binding of ANS at 
the phosphocholine nitrogen group of DPPC does not 
appear to interfere with the enzymatic reaction, suggest- 
ing that the negative phosphate oxygen group of the lipid 
is an important group in regulating the lipids activity. 
Since the fluorescence studies indicate a binding of Ca2+ 
to phospholipid, it can be concluded that, in the presence 
of enzyme, the formation of a ternary complex in which 
Ca2+ is linked to both the lipid and the enzyme is essential 
for the enzymatic reaction. 
Fig. 9B shows the effect of chlorphentermine on the 
hydrolysis of DPPC by phospholipase A2, where the 
inhibitory effect of the drug is demonstrated by the reduc- 
tion of fluorescence enhancement. The results also indi- 
cate that the presence of chlorphentermine reduces only 
the plateau level of the fluorescence intensity, but has no 
effect on the rate of fluorescence enhancement, i.e., both 
curves reach their plateau levels at approximately the 
same reaction time. This suggests that chlorphentermine 
affects mainly the binding equilibrium between ca2+  and 
the lipid that precedes the enzymatic hydrolysis reaction. 
Further studies show that phentermine exhibits little or no 
effect on the hydrolysis of DPPC by phospholipase A*, 
indicating that only strong amphiphiles whose binding 
with the lipid are significantly stabilized by hydrophobic 
interactions are able to inhibit the enzymatic degradation 
of phospholipids. Chlorphentermine possesses a stronger 
hydrophobic moiety than phentermine, thus, exhibits 
stronger binding. This may be the reason that, in chroni- 
cally treated rats, large tissue accumulation was observed 
for chlorphentermine but not for phentermine, and that 
hand, highly amphiphilic drugs, such as chlorphenter- 
mine, and to a lesser extent, phentermine, exhibit marked 
ionic interaction with phospholipids. 
Binding of amphiphilic amines has a direct effect on the 
biological activities of the lipids. The ionic interaction of 
strong amphiphiles can inhibit the metal ion-activated 
enzyme degradation of phospholipids by blocking the 
metal ion from binding to the lipid. Such inhibition may 
be an important cause for the drug-induced lipidosis. 
Furthermore, since the ionic interaction diminishes the 
amphiphilic characteristics of the lipids, it is likely that 
this interaction can also alter the physicochemical proper- 
ties of the lipids and their surface activity. I 
ManUcript received 29 Octobu 1984. 
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